Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Related Keywords
, Multiple Myeloma , Mmm , Newly Diagnosed Multiple Myeloma , Andmm , Mm Treatment , Transplant Eligible , Perseus , Griffin Trial , Perseus Trial , Daratumumab , Lenalidomide , Bortezomib , Dexamethasone , Dvrd , Quadruplet , Consolidation , Maintenance Therapy , Mash 2023 ,
comparemela.com © 2020. All Rights Reserved.